## Abstract The original article to which this Erratum refers was published in the September, 2004 issue of __Movement__ Disorders (2004) 19 (9) 997β1005.
The history of dopamine and levodopa in the treatment of Parkinson's disease
β Scribed by Stanley Fahn
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 224 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the βgold standardβ against which new agents must be compared. However, there remain two areas of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes motor
## Abstract Companion letters have been published in __Movement__ Disorders: Current Controversies: Levodopa in the Treatment of Parkinson's Disease, by Sharma, Vassallo, and Ross and Reply: Levodopa in the Treatment of Parkinson's Disease, by Olanow, Agid, and Mizuno.
## Abstract Companion letters have been published in __Movement__ Disorders: Levodopa in the Treatment of Parkinson's Disease: Current Controversies, by Gerlach, Reichmann, and Riederer and Reply: Levodopa in the Treatment of Parkinson's Disease, by Olanow, Agid, and Mizuno.
## Abstract The original articles to which this Letter refers have published in __Movement__ Disorders: Current Controversies: Levodopa in the Treatment of Parkinson's Disease, by Sharma, Vassallo, and Ross and Levodopa in the Treatment of Parkinson's Disease: Current Controversies, by Gerlach, Rei